Jan
16
2020
On demand

A pragmatic approach to the buy vs build manufacturing dilemma

Sponsor
A pragmatic approach to the buy vs build manufacturing dilemma

The decision to outsource manufacturing or produce a therapeutic product in house plagues many biopharmaceutical executives. Each decision requires a careful assessment of multiple variables such as timelines,IP protection, forecast, capital allocation, technical capabilities, and market strategy. Every situation is unique and typically requires compromises and often results in valuable lessons learned.We will present a case study of one economic assessment of a buy versus build decision model. The panel will discuss other scenarios to generate a useful discussion of the possible options and the potential outcomes.

Attendees will learn:

  • Financial modeling of buy vs build scenarios
  • Considerations when manufacturing at a CMO
  • Benefits of outsourcing or insourcing
  • In-house manufacturing options for retrofitting existing structure, stick-built or modular builds
  • Technical challenges when manufacturing gene therapies

Nacim  Haderbache
Nacim Haderbache
Commercial Strategy Leader at Cytiva
Carol Houts
Carol Houts
Director, Regulatory & Quality at Germfree Laboratories
Joseph Phillips
Joseph Phillips
Senior Vice President & Head of Pharmaceutical Development at ARMAGEN, INC.

SPEAKERS

Nacim  Haderbache
Nacim Haderbache
Commercial Strategy Leader at Cytiva
Carol Houts
Carol Houts
Director, Regulatory & Quality at Germfree Laboratories
Joseph Phillips
Joseph Phillips
Senior Vice President & Head of Pharmaceutical Development at ARMAGEN, INC.

You might also like